Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05071482
Other study ID # HS-2020-09TJ
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 16, 2021
Est. completion date October 30, 2025

Study information

Verified date September 2021
Source Institute of Hematology & Blood Diseases Hospital
Contact Jianxiang Wang, Dr.
Phone 86-22-23909120
Email wangjx@medmail.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Compared with patients with philadelphia chromosome-negative Acute Lymphoblastic Leukemia (Ph- ALL), patients with Ph-positive (Ph+) ALL exhibit a comparatively poor prognosis. Fortunately, significant improvements have been found in response rates, disease-free survival (DFS), and overall survival (OS) for patients with Ph+ ALL with the introduction of tyrosine kinase inhibitor (TKI) therapy to treatment regimens. Based on improvements in efficacy and tolerability, next-generation TKIs have been widely used in first-line treatment for chronic myeloid leukemia (CML). Flumatinib, a TKI with more potent binding affinity for BCR-ABL1 tyrosine kinase than imatinib, demonstrated higher rates of responses, faster and deeper responses in FESTnd trial, which suggested that flumatinib might show improved clinical efficacy for treating Ph+ ALL compared with imatinib. The investigators therefore hypothesized that the addition of flumatinib to combinatorial chemotherapy regimen would demonstrate greater efficacy compared with the prior use of imatinib in treating Ph+ ALL. This study explored the safety and efficacy of flumatinib versus imatinib when combined with multi-agent chemotherapy in patients with newly diagnosed Ph+ ALL.


Recruitment information / eligibility

Status Recruiting
Enrollment 238
Est. completion date October 30, 2025
Est. primary completion date October 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Patients aged 18 to 65 years, male or female; 2. Newly diagnosed Philadelphia chromosome positive(either t(9;22) and/or BCR-ABL positive and/ or FISH positive) acute lymphoblastic leukemia; Patients will be diagnosed according to morphologic,immunologic, cytogenetic and molecular(MICM) criteria, including bone marrow morphology, immunophenotype, cytogenetic and molecular genetic (BCR/ABL gene, qualitative and quantitative analysis) examination. 3. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2; 4. Adequate end organ function as defined by: Total bilirubin = 1.5 x upper limit of normal(ULN); serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) = 2.5 x ULN or =5 x ULN if leukemic involvement of the liver is present; Creatinine = 1.5 x ULN; Serum amylase and lipase = 1.5 x ULN; Alkaline phosphatase = 2.5 x ULN unless considered tumor related; normal electrolytes: Potassium = LLN; Magnesium = LLN; Phosphorus = LLN; 5. Cardiac color Doppler ultrasound ejection fraction = 45%; 6. Subject has provided written informed consent prior to any screening procedure; Exclusion Criteria: 1. Lymphoid blast crisis of chronic myelocytic leukemia (CML); 2. Previous or ongoing systemic anti-ALL therapy (including but not restricted to TKI and/or radiotherapy, except for appropriate pre-treatment); 3. Patients with clinical manifestations of central or extramedullary invasion of leukemia at diagnosis; 4. Identification of T315I mutation; 5. Concurrent participation in another clinical study with an investigational medical product; 6. Any concurrent severe and/or uncontrolled medical condition, which could, in the opinion of the investigator, compromise participation in the study; 7. History of neurological or psychiatric disorders, including epilepsy or dementia; 8. Major surgery within 4 weeks or failure to recover from previous surgery; 9. Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention; 10. Female patients who are pregnant or breast feeding or patients of childbearing potential and male patients whose sexual partner(s) are women of childbearing potential not willing to use a highly effective method of contraception; 11. Clinically significant, uncontrolled or active cardiovascular disease, specifically including, but not restricted to: any history of myocardial infarction, stroke, or revascularization; unstable angina or transient ischemic attack within 6 months prior to enrolment; congestive heart failure within 6 months prior to enrolment or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards; history of clinically significant (as determined by the treating physician) atrial arrhythmia; any history of ventricular arrhythmia; any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism;Uncontrolled hypertension; 12. Active known positive HIV serology; 13. Active serious infection not controlled by oral or intravenous antibiotics; 14. Patients with known allergies or contraindications to the study drug; 15. Patients with bleeding disorders unrelated to ALL.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Flumatinib
Flumatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Flumatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
Imatinib
Imatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Imatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.

Locations

Country Name City State
China Institute of Hematology & Blood Diseases Hospital Tianjin

Sponsors (1)

Lead Sponsor Collaborator
wang, jianxiang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other ABL kinase region mutation status at molecular relapse (MREL) and hematologic relapse (HREL) up to 24 months
Other The plasma and cerebrospinal fluid (CSF) level of flumatinib up to 3 months
Primary Relapse free survival From the date of complete remission(CR) until the date of documented relapse or death due to any cause or the last follow-up day up to 24 months
Secondary The rate of adverse events The incidence and severity of neutropenia, anemia, rash, hypophosphatemia, edema, limb pain, and other adverse events. through study completion, up to 24 months
Secondary The composite CR rate Both CR and molecular CR are obtained at the end of induction up to 2 month
Secondary The complete remission (CR) rate,CRi rate and overall remission rate(ORR) up to 2 month
Secondary The minimal residual disease (MRD) negative rate by Flow Cytometry (FCM) up to 24 months
Secondary The molecular CR rate up to 6 months
Secondary The rate of primary induction failure(PIF) up to 6 months
Secondary The duration of molecular CR up to 24 months
Secondary The duration of CR up to 24 months
Secondary Time to treatment failure up to 24 months
Secondary The cumulative recurrence rate up to 24 months
Secondary The CNS recurrence rate up to 24 months
Secondary Event free survival(EFS) up to 24 months
Secondary Overall survival(OS) up to 24 months
Secondary The rate of interruption and discontinuation due to AE up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT01956630 - Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Phase 1/Phase 2
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Enrolling by invitation NCT01728402 - Pathogenesis of Hematologic Malignancies
Active, not recruiting NCT03595800 - Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen Phase 3
Completed NCT02440178 - Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia Phase 2
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Completed NCT04597086 - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients N/A
Terminated NCT03588936 - Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Phase 1
Recruiting NCT05521204 - Olverembatinib for FGFR1-rearranged Neoplasms Phase 2
Not yet recruiting NCT04084327 - Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Not yet recruiting NCT06026839 - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
Completed NCT00520130 - Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Phase 1/Phase 2